articleThe Lancet OncologySep 3, 2015Closed access

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

CLChristophe Le TourneauJDJean-Pierre DelordAGAnthony GonçalvèsCGCéline GavoilleCDCoraline Dubot

Institut Curie · Université de Versailles Saint-Quentin-en-Yvelines · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,113
total citations
FWCI
54.40
Percentile
100%
References
29
Citations per year

Authors

23

Topics & keywords

Topics
Keywords
  • Medicine
  • Proof of concept
  • Open label
  • Profiling (computer programming)
  • Oncology
  • Randomized controlled trial
  • Cancer therapy
  • Internal medicine
No related works found for this paper.

Funding